CPI-613: Phase I started

Cornerstone said the Wake Forest Baptist Medical Center and the NCI began an open-label, dose-escalation, U.S. Phase I trial to evaluate IV CPI-613 in combination with IV Treanda bendamustine in about 14 patients with Hodgkin's lymphoma or NHL. Patients will receive CPI-613 on days 1-4 of the first week and on days 1 and 4 of the second and third week in a 4-week cycle for up to 6 cycles. CPI-613 is in multiple clinical trials, including Phase II trials for small cell lung cancer (SCLC), myelodysplastic syndrome (MDS) and pancreatic cancer.

The compound has Orphan Drug designation in the U.S. to treat pancreatic cancer, MDS and acute myelogenous leukemia (AML). ...